Future studies will be essential to elucidate the molecular mechanisms driving the differentiation of these subsets and to explore potential therapeutic strategies that leverage naïve CD8 T cell heterogeneity to improve immune protection against infections and cancer, and to regulate excessive CD8 T cell immunity. Here, CD8A is linked to cancer.